Valar Labs
Offers assistance services for cancer treatment through Artificial Intelligence.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $22.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Valar Labs operates at the intersection of artificial intelligence (AI) and oncology, focusing on reducing uncertainty in cancer treatment decisions. The company provides AI-driven diagnostic tests that analyze pathology slides to predict how tumors will respond to various treatments. This helps oncologists and patients make more informed decisions about therapy options. Valar Labs primarily serves oncologists and their patients, operating within the precision oncology market. The business model revolves around the development and sale of diagnostic tests, such as Vesta, the world's first AI test for predicting treatment response in bladder cancer. Revenue is generated through the sale of these diagnostic tests to healthcare providers and institutions. The company recently secured $22 million in Series A funding to advance its AI technology and expand its applications to other types of cancer.
Keywords: AI diagnostics, oncology, precision medicine, pathology slides, tumor analysis, treatment prediction, cancer care, healthcare technology, Series A funding, Vesta test.